Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy

Journal of Nephrology

Volumn 22, Issue 3, 2009, Pages 387-396

  Bazzi, Claudio ^a   Rizza, Virginia ^b   Paparella, Maria ^b   Casellato, Daniela ^b   Napodano, Pietro ^b   Olivieri, Giulia ^b   D'Amico, Giuseppe ^a  

^a Fondazione d'Amico per la Ricerca Sulle Malattie Renali   (Italy)

^b SAN CARLO BORROMEO HOSPITAL   (Italy)

Author keywords

ACE inhibitors; Fractional excretion of IgG; IgA nephropathy; Renoprotection

Indexed keywords

ALPHA 1 MICROGLOBULIN; CREATINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN G;

ADULT; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; FEMALE; GLOMERULOSCLEROSIS; HUMAN; HUMAN TISSUE; HYALINE DEGENERATION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROTEINURIA; RENAL PROTECTION; RISK FACTOR; URINARY EXCRETION; ADOLESCENT; AGED; BIOPSY; CHILD; KIDNEY; MIDDLE AGED; PATHOLOGY; URINE;

ADOLESCENT; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOPSY; CHILD; DISEASE PROGRESSION; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOGLOBULIN G; KIDNEY; MALE; MIDDLE AGED; PROTEINURIA; RISK FACTORS;

EID: 69449090806     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. D'Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol. 2004;24:179-196.
2. Dillon JJ. Angiotensin-converting enzyme inhibitors and angiotensin receptors blockers for IgA nephropathy. Semin Nephrol. 2004;24:218-224.
3. Feriozzi S, Pierucci A, Roscia E, et al. Angiotensin converting enzyme inhibition delays the progression of chronic renal failure in hypertensive patients with immunoglobulin A nephropathy. J Hypertens. 1989;(Suppl 7):S63-S64.
4. Cattran DC, Greenwood C, Ritchie S. Long-term benefit of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis. 1994;23:247-254.
5. Bannister KM, Weaver A, Clarkson AR, et al. Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy. Contrib Nephrol. 1995;111:184-193.
6. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet. 2003;361:117-124.
7. Praga M, Gutierrez E, Gonzales E, et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol. 2003;14:1578-1583.
8. Yang Y, Ohta K, Shimizu M, et al. Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy. Clin Nephrol. 2005;64:35-40.
9. Li PK, Leung CB, Chow KM, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis. 2006;47:751-760.
10. Coppo R, Peruzzi L, Amore A, et al. IgACE: A placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol. 2007;18:1880-1888.
11. Remuzzi A, Perico N, Sangalli F, et al. ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol. 1999;276:F456-F466.
12. Russo D, Pisani A, Balletta MM, et al. Additive proteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis. 1999;33:851-856.
13. The GISEN Group. Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857-1863.
14. Bazzi C, Petrini C, Rizza V, et al. Fractional excretion of IgG predicts renal outcome and response to therapy in primary focal segmental glomerulosclerosis: a pilot study. Am J Kidney Dis. 2003;41:328-335.
15. D'Amico G, Ferrario F, Colasanti G, et al. IgA-mesangial nephropathy (Berger's disease) with rapid decline of renal function. Clin Nephrol. 1981;16:251-257.
16. Risdon RA, Sloper JC, De Wardener HE. Relationship between renal function and histologic changes found in renal biopsy specimens from patients with persistent glomerular nephritis. Lancet. 1968;363:363-366.
17. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39:561-577.
18. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: Part II: analysis and examples. Br J Cancer. 1977;35:1-39.
19. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
20. Pozzi C, Del Vecchio L, Casartelli D, et al. ACE inhibitors and angiotensin II receptor blockers in IgA nephropathy: the ACEARB study. J Nephrol. 2006;19:508-514.
21. Eitner F, Ackermann D, Hilgers RD, Floege J. Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol. J Nephrol. 2008;21:284-289.
22. Glassock RJ. The treatment of idiopathic membranous nephropathy: a dilemma or a conundrum? Am J Kidney Dis. 2004;44:562-566.
23. Jager KJ, Stel VS, Wanner C, et al. The valuable contribution of observational studies to nephrology. Kidney Int. 2007;72:671-675.
24. Bazzi C, Petrini C, Rizza V, et al. Urinary excretion of IgG and α1-microglobulin predicts clinical course better than the extent of proteinuria in membranous nephropathy. Am J Kidney Dis. 2001;38:240-248.
25. Bazzi C, Petrini C, Rizza V, et al. Relationship between components of proteinuria, histological lesions and progression to chronic renal failure in IgA nephropathy. Abstract. Tenth international symposium on IgA nephropathy, Saint-Etienne, (France), March 26-27 2004; Abstract Book, page 79.
26. Reddan DN, Owen WF. IgA nephropathy and inhibitors of the renin angiotensin system: Is reduction of proteinuria adequate proof of efficacy? Am J Kidney Dis. 2001;38:182-185.
27. Reich HN, Troyanov S, Scholey JW, et al. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007;18:3177-3183.
28. Cattran DC. Is proteinuria reduction by angiotensin-converting enzyme inhibition enough to prove its role in renal protection in IgA nephropathy? J Am Soc Nephrol. 2007;18:1633-1634.
29. Campbell RC. The renin-angiotensin system: a 21st century perspective. J Am Soc Nephrol. 2004;15:1963-1964.
30. Suzuki Y, Ruiz-Ortega M, Lorenzo O, et al. Inflammation and angiotensin II. Int J Biochem Cell Biol. 2003;35:881-900.
31. Agarwal R, Campbell R, Warnock D. Oxidative stress in hypertension and chronic kidney disease: role of angiotensin II. Semin Nephrol. 2004;24:101-114.
32. Jaimes EA, Galceran JM, Raij L. Angiotensin II induces superoxide anion production by mesangial cells. Kidney Int. 1998;54:775-784